GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| Merck & Co. (NYSE: MRK) | Delayed: 148.36 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.36 | 52 Week High | $65.46 | |||
| Open | $148.36 | 52 Week Low | $47.97 | |||
| Day High | $148.36 | P/E | 100.93 | |||
| Day Low | $148.36 | EPS | $1.47 | |||
| Volume | 7,512 | |||||
